In vitro inhibitory effects of plumbagin, the promising antimalarial candidate, on human cytochrome P450 enzymes

Asian Pacific Journal of Tropical Medicine

Volumn 8, Issue 11, 2015, Pages 914-918

  Sumsakul, Wiriyaporn ^a   Chaijaroenkul, Wanna ^a   Na Bangchang, Kesara ^a  

^a THAMMASAT UNIVERSITY   (Thailand)

Author keywords

Cytochrome P450; Enzyme inhibition; Human liver microsomes; Metabolism; Plumbagin

Indexed keywords

ALPHA NAPHTHOFLAVONE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; KETOCONAZOLE; NIFEDIPINE; NOOTKATONE; OMEPRAZOLE; PARACETAMOL; PHENACETIN; PLUMBAGIN; UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LIVER MICROSOME; PRIORITY JOURNAL;

EID: 84947911803     PISSN: 19957645     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apjtm.2015.10.016     Document Type: Article

References (24)

1. Na-Bangchang K., Congpuong K. Current malaria status and distribution of drug resistance in East and Southeast Asia with special focus to Thailand. Tohoku J Exp Med 2007, 211(2):99-113.
2. Paiva S.R., Silva Marques S., Figueiredo M.R., Auxiliadora M. Plumbaginales: a pharmacological approach. Floresta e Ambiente 2003, 10(1):98-105.
3. Bhargava S.K. Effects of plumbagin on reproductive function of male dog. Indian J Exp Biol 1984, 22(3):153-156.
4. Itoigawa M., Takeya K., Furukawa H. Cardiotonic action of plumbagin on guinea-pig papillary muscle. Planta Med 1991, 57(4):317-319.
5. Premakumari P., Rathinam K., Santhakumari G. Antifertility activity of plumbagin. Indian J Med Res 1977, 65(6):829-838.
6. Sandur S.K., Ichikawa H., Sethi G., Ahn K.S., Aggarwal B.B. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) suppresses NF-kappaB activation and NF-kappaB-regulated gene products through modulation of p65 and IkappaBalpha kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents. J Biol Chem 2006, 281(25):17023-17033.
7. Thiengsusuk A., Chaijaroenkul W., Na-Bangchang K. Antimalarial activities of medicinal plants and herbal formulations used in Thai traditional medicine. Parasitol Res 2013, 112(4):1475-1481.
8. Sumsakul W., Plengsuriyakarn T., Chaijaroenkul W., Viyanant V., Karbwang J., Na-Bangchang K. Antimalarial activity of plumbagin in vitro and in animal models. BMC Complement Altern Med 2014, 14:15.
9. Zhou S., Gao Y., Jiang W., Huang M., Xu A., Paxton J.W. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003, 35(1):35-98.
10. Lin J.H., Lu A.Y. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998, 35(5):361-390.
11. Lavhekar S., Lohade A., Coutinho E., Iyer K. Estimation of microsomal CYP1A2 activity by high performance liquid chromatography. Indian J Pharm Sci 2006, 68(2):258.
12. Tassaneeyakul W., Guo L., Fukuda K., Ohta T., Yamazoe Y. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch Biochem Biophys 2000, 378(2):356-363.
13. Patki K., Von Moltke L., Greenblatt D. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos 2003, 31(7):938-944.
14. Foti R.S., Pearson J.T., Rock D.A., Wahlstrom J.L., Wienkers L.C. In vitro inhibition of multiple cytochrome P450 isoforms by xanthone derivatives from mangosteen extract. Drug Metab Dispos 2009, 37(9):1848-1855.
15. He N., Edeki T. The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am J Ther 2004, 11(3):206-212.
16. Wu J.J., Ai C.Z., Liu Y., Zhang Y.Y., Jiang M., Fan X.R., et al. Interactions between phytochemicals from traditional Chinese medicines and human cytochrome P450 enzymes. Curr Drug Metab 2012, 13(5):599-614.
17. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994, 270(1):414-423.
18. Desta Z., Zhao X., Shin J.G., Flockhart D.A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002, 41(12):913-958.
19. Fan L., Wang G., Wang L.S., Chen Y., Zhang W., Huang Y.F., et al. Herbal medicine Yin Zhi Huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole. Acta Pharmacol Sin 2007, 28(10):1685-1692.
20. Wang L.S., Zhou G., Zhu B., Wu J., Wang J.G., El-Aty A.M.A., et al. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 2004, 75(3):191-197.
21. Yin O.Q., Tomlinson B., Waye M.M., Chow A.H., Chow M.S. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004, 14(12):841-850.
22. Rendic S., Di Carlo F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997, 29(1-2):413-580.
23. Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 2004, 369(1):89-104.
24. Izzo A.A., Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001, 61(15):2163-2175.